Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma (ICI-RT-1)
Retrospective, Multicentric, Observational Study to Evaluate the Efficacy and Safety of the Combination of an Immune Checkpoint Inhibitor (ICI) and Radiotherapy (RT) in Patients With Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL)
Sponsor: Ospedale Maggiore Di Trieste
This observational or N/A phase trial investigates Hodgkin Lymphoma and Immune Checkpoint Inhibitor and is currently ongoing. Ospedale Maggiore Di Trieste leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Nov 2022 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jan 2021 — Nov 2022 [monthly]
Recruiting
-
Oct 2020 — Jan 2021 [monthly]
Recruiting
▶ Show 1 earlier version
-
Jul 2020 — Oct 2020 [monthly]
Recruiting
First recorded
Jun 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ospedale Maggiore Di Trieste
For direct contact, visit the study record on ClinicalTrials.gov .